FDA Scales Back Near-Term Goals For Sentinel Postmarket Data Network
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Janet Woodcock said the agency has not been able to overcome budgetary restrictions that hamper previously discussed plans to develop the Sentinel postmarket drug safety surveillance system into a much broader national resource.